Search Results

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen).

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 20 company-sponsored presentations from its nipocalimab and autoantibody diseases research program will be showcased at the 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Meeting from November 1-4 in Phoenix, Arizona.

Elektrofi, Inc. announced that it has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.

Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.

- Company listed in Research and Markets’ announcement and description of new research report on the U.S. Breast Cancer Screening and Diagnostic Market- - “U.S. breast cancer screening and diagnostic [device] market was valued at $1.55 billion in 2024 and is anticipated to reach $2.34 billion by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-20301"- -Report supports Company’s regulatory strategy for IzoView Breast CT, reinforces high demand for new breast imaging modalities, strengthens the potential for rapid market adoption and significant market share -